Inotiv, Inc. · NASDAQ:NOTV
Inotiv — Bioanalytical Systems — Noble Financial Capital Markets 11th Annual Investor Conference (January 2015)
19 slides from Inotiv's conference presentation, Jan 20, 2015
Slide 1: Noble Financial Capital Markets 11th Annual Investor Conference
NOBLE FINANCIAL CAPITAL MARKETS 11 TH ANNUAL INVESTOR CONFERENCE Jacqueline M. Lemke President & CEO January 2015
Slide 2: Safe Harbor Statement
MARKET FOCUSED INNOVATIVE Safe Harbor Statement Matters discussed in this Presentation contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . When used in this document, the words "anticipate," "believe," "estimate," "may," "intend," "expect
Slide 3: Today's Discussion: The Market – Trends, Potential, Focus
MARKET FOCUSED INNOVATIVE The Market – Trends, Potential, Focus » Macro trends of CRO industry » Benchmark BASi w leaders » Build shareholder value The BASi Difference » Innovative , flexible and creative » Redefining possibilities by creating solutions » Huge upward market potential Today’s Discuss
Slide 4: Outsourcing is Here to Stay
MARKET FOCUSED » Contract research outsourcing gained m omentum in the late 1990s. » There are now more scientists in CROs in large Pharma. » 2012 revenue for the top 11 CROs: Global $ 13.7 Bn - 3 year CAGR 12.1% North Amer $6.1 Bn - 3 year CAGR 11.9 % » FY 2012 BASi CRO revenues were $21 M » Revenu
Slide 5: Diverse Competitors
MARKET FOCUSED Basic Research Discovery Pre - Clinical IND Clinical Phase 1 - 3 NDA Post Approval Diverse Competitors » Spanning the drug discovery value chain » Fragmented & diverse » Competitors are also our customers Company Name Headcount Revenue (M USD) % North America Preclinical BioA PharmA B
Slide 6: Benchmarking Leaders
MARKET FOCUSED » Post restructuring, BASi Gross Margin comparable to large competitors » Goal is to grow EBITDA margin » Leverage cost position Benchmarking Leaders Company Name Headcount Revenue (M USD) % North America Gross Margin EBITDA Margin Price per Share Mkt Cap Bioanalytical Systems Inc 150
Slide 7: CRO Market Trends
MARKET FOCUSED L arge and Mid - Size CROs » Heavily dependent upon major client a greements » Targeting new clients » Buying capabilities BASi » Established ability to serve the biotech market » Further growing large molecule capabilities » Created flexibility and sustainability throughout cycles vi
Slide 8: Laboratory Instruments
MARKET FOCUSED BASi Epsilon Electrochemical Analyzer » First EC analyzer on the market » Loyal customer base » Several competitors » Much greater potential a pplication than drug discovery BASi Culex® In vivo Sampling » C ompetition is the manual sampling market – 8,500 animal labs in US alone » 7 o
Slide 9: Stock Price Trend Post-Restructuring
MARKET FOCUSED INNOVATIVE Stock Price Trend Post - Restructuring Trending with and Over the Market
Slide 10: BASi Focus
MARKET FOCUSED » Invest in experienced talent » Restructure financials » Actively face the market – » BASi Culex® workshops » grant program » Brand messaging » Invest in tools to i ncrease efficiency BASi Focus » Post Restructuring EBITDA has increased substantially, even on lower revenue
Slide 11: The BASi Difference
INNOVATIVE Services » Able to substantially reduce time to market » Developed more sensitive automated detection methodology Instruments » Revolutionary BASi Culex® automated technology v primitive manual sampling protocol Forward Thinkers The BASi Difference » Innovative, flexible and creative » Re
Slide 12: Innovation in CRO Services
MARKET FOCUSED INNOVATIVE Innovation in CRO Services Flexible – Creative - Custom Built a relationship of trust, challenge and continuous collaboration with a start - up biotech beginning in 2004 Reduced timeline for NDA enabling study from 10 years to 5 years. Drug to treat hepatitis C was approved
Slide 13: Innovation in CRO Services: Custom Methodology
INNOVATIVE » A start up biotech developing a novel cure for l ife - threatening diseases related to impaired blood flow. » Requested a PK study and provided a manual extraction method at required a large sample volume. » We created a more sensitive automated detection methodology » reduced sample si
Slide 14: Customization Success
INNOVATIVE » The industry estimate is that only 1 in 10,000 potential compounds make it to new drug status . » The role of a CRO is to provide the research needed to screen c ompounds. » Often, the data results in a decision to d iscontinue p ursuing drug Approval. » BASi , is less than ¼ of 1 perce
Slide 15: Instrument Innovation
INNOVATIVE » Designed to allow the lab technician to program the automatic dosing and blood draws, BASi’s Culex® technology provides better data using less technicians, less test subjects and less time. » Allows for more predictive d ata than data gathered under Stress. » BASi’s Culex® patented auto
Slide 16: Clearly Superior Results
INNOVATIVE Clearly Superior Results BASi Culex® Automated In vivo sampling DSI PhysioTel™ Digital implanted radio telemetry
Slide 17: A Typical PK Study – Automated v Manual
INNOVATIVE A Typical PK Study – Automated V Manual » 50 % fewer lab technicians » 92 % fewer test subjects » 88% less time » b etter data » Saves time, Saves money & Saves lives » The market is slow to change » BASi will continue to innovate Education & Outreach
Slide 18: Our Clients Say it Best
MARKET FOCUSED INNOVATIVE Our Clients Say it Best “I’ve had the pleasure of working with Philip Downing and his staff at BASi during the past half year. We’re a small start up trying to develop our compound through phase 2 before our funds run out. We considered working with a larger CRO but soon fo
Slide 19: Contact
MARKET FOCUSED INNOVATIVE Contact Bioanalytical Systems, Inc. Purdue Research Park 2701 Kent Avenue West Lafayette, IN 47906 Jacqueline M. Lemke President & CEO Phone: (765) 463 - 4527 Email: jlemke@BASinc.com Jeffrey Potrzebowski CFO & Vice President, Finance Phone: 765.497.5809 Email: jpotrzebowsk